PensionDanmark Pensionsforsikringsaktieselskab Has $21.51 Million Holdings in Stryker Corporation $SYK

PensionDanmark Pensionsforsikringsaktieselskab lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 4.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 68,326 shares of the medical technology company’s stock after purchasing an additional 3,040 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Stryker were worth $21,512,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in SYK. Mirabaud & Cie SA acquired a new stake in Stryker during the 2nd quarter valued at approximately $250,000. Assenagon Asset Management S.A. boosted its stake in shares of Stryker by 263.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 38,699 shares of the medical technology company’s stock valued at $12,184,000 after purchasing an additional 28,037 shares during the last quarter. Manitou Investment Management Ltd. boosted its stake in shares of Stryker by 40.5% in the 2nd quarter. Manitou Investment Management Ltd. now owns 117,276 shares of the medical technology company’s stock valued at $36,923,000 after purchasing an additional 33,812 shares during the last quarter. Red Spruce Capital LLC increased its position in shares of Stryker by 24.3% during the second quarter. Red Spruce Capital LLC now owns 1,642 shares of the medical technology company’s stock worth $517,000 after buying an additional 321 shares during the period. Finally, Westmount Partners LLC raised its stake in Stryker by 20.0% during the second quarter. Westmount Partners LLC now owns 964 shares of the medical technology company’s stock worth $303,000 after buying an additional 161 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 323,264 shares of company stock valued at $100,659,489. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SYK. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Wolfe Research set a $375.00 price objective on Stryker in a research report on Friday, July 31st. Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday, May 1st. Leerink Partners cut their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Finally, Canaccord Genuity Group decreased their target price on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Price Performance

Shares of NYSE SYK opened at $336.91 on Friday. The firm’s 50-day moving average price is $319.45 and its 200-day moving average price is $334.10. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The firm has a market capitalization of $129.23 billion, a P/E ratio of 34.91, a P/E/G ratio of 2.15 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.